Discordance Between Clinicopathological and Molecular Risk Classification in Endometrial Carcinoma: A Prospective Observational Study

Background: Endometrial carcinoma is commonly managed using clinicopathological risk stratification to guide adjuvant treatment. However, p53 and mismatch repair (MMR) status may identify biological risks not captured by conventional classifications. Local evidence regarding discordance between clinicopathological and molecular risk profiles remains limited. This study aimed to assess this discordance and to describe treatment allocation and one-year outcomes among patients with molecular abnormalities. Methods: This prospective observational study was conducted at the National Institute of Cancer Research and Hospital, Dhaka, from October 2021 to May 2023 and included 42 women with endometrial carcinoma who underwent definitive surgery. Risk was assigned by the ESGO/ESTRO/ESP 2021 consensus, p53 and MMR proteins were assessed by immunohistochemistry and patients were followed for one year. Fisher's exact test was used for outcome comparisons. Results: Conventional classification identified 17 low-risk (40.5%) and 18 high-risk (42.9%) patients, with seven in intermediate categories. Abnormal p53 expression was found in five patients (11.9%) and MMR deficiency in 16 (38.1%). Among the 17 low-risk patients, one (5.88%) had abnormal p53 and seven (41.17%) were MMR deficient; among the 18 high-risk patients, four (22.2%) had abnormal p53 and five (27.78%) were MMR deficient. No low-risk patient with a molecular abnormality received adjuvant treatment or progressed. Freedom from progression was 60.0% with abnormal p53 versus 97.3% with normal p53 (p=0.001) and 93.8% versus 92.3% for MMR-deficient and MMR-retained tumours (p=0.414). Conclusion: Molecular abnormalities occurred in conventionally low-risk endometrial carcinoma, indicating that clinicopathological classification alone does not capture molecular risk. Combined assessment may refine risk stratification, pending larger confirmatory studies.

Authors

Institutions

Publication Details

Journal
Scholars International Journal of Obstetrics and Gynecology
Published
2026-11-02
DOI
https://doi.org/10.36348/sijog.2026.v09i11.002
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discordance Between Clinicopathological and Molecular Risk Classification in Endometrial Carcinoma: A Prospective Observational Study

Rifat Ara, Shakila Laizo, Shahana Parvin, Sadia Jabeen et al.
Scholars International Journal of Obstetrics and Gynecology
Endometrial and Cervical Cancer Treatments
article

Discordance Between Clinicopathological and Molecular Risk Classification in Endometrial Carcinoma: A Prospective Observational Study

Rifat Ara, Shakila Laizo, Shahana Parvin, Sadia Jabeen, Susmita Sarker
article en

Abstract

Background: Endometrial carcinoma is commonly managed using clinicopathological risk stratification to guide adjuvant treatment. However, p53 and mismatch repair (MMR) status may identify biological risks not captured by conventional classifications. Local evidence regarding discordance between clinicopathological and molecular risk profiles remains limited. This study aimed to assess this discordance and to describe treatment allocation and one-year outcomes among patients with molecular abnormalities. Methods: This prospective observational study was conducted at the National Institute of Cancer Research and Hospital, Dhaka, from October 2021 to May 2023 and included 42 women with endometrial carcinoma who underwent definitive surgery. Risk was assigned by the ESGO/ESTRO/ESP 2021 consensus, p53 and MMR proteins were assessed by immunohistochemistry and patients were followed for one year. Fisher's exact test was used for outcome comparisons. Results: Conventional classification identified 17 low-risk (40.5%) and 18 high-risk (42.9%) patients, with seven in intermediate categories. Abnormal p53 expression was found in five patients (11.9%) and MMR deficiency in 16 (38.1%). Among the 17 low-risk patients, one (5.88%) had abnormal p53 and seven (41.17%) were MMR deficient; among the 18 high-risk patients, four (22.2%) had abnormal p53 and five (27.78%) were MMR deficient. No low-risk patient with a molecular abnormality received adjuvant treatment or progressed. Freedom from progression was 60.0% with abnormal p53 versus 97.3% with normal p53 (p=0.001) and 93.8% versus 92.3% for MMR-deficient and MMR-retained tumours (p=0.414). Conclusion: Molecular abnormalities occurred in conventionally low-risk endometrial carcinoma, indicating that clinicopathological classification alone does not capture molecular risk. Combined assessment may refine risk stratification, pending larger confirmatory studies.

Scholars International Journal of Obstetrics and GynecologyVol. 9(11)
National Institute of Cancer Research and Hospital (BD), Dhaka Medical College and Hospital (BD)
Openalex Percentile: Top 9%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon